New psoriasis pill enters Mid-Stage trial
NCT ID NCT07158268
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests an oral tablet called HSK47388 in 220 adults with moderate-to-severe plaque psoriasis. Participants take the drug or a placebo once daily for 16 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75% compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSK47388 (oral tablet)
- What this could lead to
- If successful, this could lead to a new daily pill to control moderate-to-severe plaque psoriasis, reducing skin plaques and improving quality of life.
- What could go wrong
- This is an early phase 2 trial with only 220 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection clear psoriasis when other biologics fail?
- Can a gel tame psoriasis? new antibody fragment put to the test
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a new drug called ZP9830 calm psoriasis Flare-Ups?
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial